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Abstract
The emergency hospital is intended to prevent transmission of COVID-19 in the community by isolating patients without symptoms, with mild or moderate 
symptoms. This study evaluated the clinical characteristics and outcomes of COVID-19 patients who were admitted to this facility. This retrospective study re-
viewed data of patients treated at the National Emergency Hospital Wisma Atlet Kemayoran in Jakarta, Indonesia, from March 23 to April 30, 2020. Patient 
characteristics (clinical symptoms, laboratory test results, Chest X-Ray, SARS-CoV-2 immunoserology, and RT-PCR results from nasopharyngeal/ 
oropharyngeal preparations) were compared between severity groups. There were 413 COVID-19 cases analyzed, of which 190 (46%) were asymptomatic, 
93 (22.5%) were mild, and 130 (31.5%) were moderate cases. Most asymptomatic cases were male, with young age, and without comorbidity. Mild cases 
were dominated by female and young patients, while most moderate cases were male and older patients. The number of patients with comorbidities was 
higher in mild and mod-erate cases. The patient’s overall outcome was good and did not differ based on the severity of symptoms. Despite the many 
challenges, patients with moderate symptoms can be safely treated in the emergency hospital.
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Introduction
By the time the World Health Organization (WHO)
declared a pandemic of COVID-19 in early March 2020,
the disease had already reached many countries world-
wide, including Indonesia. Indonesia is a middle-income
country with per capita health expenditure among the
lowest in the category.1 The COVID-19 pandemic has
been expected to hit low- and middle-income countries
(LMICs) the hardest. The low socioeconomic status of
the population, as characterized by overcrowded living
conditions, limited access to daily basic needs (e.g., food,
clean water), and reliance on daily earnings, makes phys-
ical distancing and lockdown almost impossible.
Furthermore, the care of COVID-19 patients is challeng-
ing as the already limited health care capacities become
quickly overwhelmed.  
Confirmed COVID-19 was first reported in Indonesia
on March 2, 2020;2 since then, Jakarta became the first
and ongoing epicenter. The number of positive cases had
risen dramatically to more than 250,000 by the time this
manuscript was prepared, and 9,800 deaths were record-
ed, the highest in Southeast Asia.3 During the early phase
of the pandemic, Indonesia faced a challenging situation,
including lack of personal protective equipment (PPE), 
medical supplies and diagnostic tools, unequal medical 
services distribution, and no standardized national guide-
lines.4,5 This situation was complicated by inadequate/in-
consistent public information from the government. One 
of the recommendations for handling the COVID-19 
pandemic in a resource-limited setting is shifting public 
facilities into emergency hospitals. The Indonesian Gov-
ernment adopted this strategy by converting four apart-
ment towers of Wisma Atlet Kemayoran in Jakarta into 
an emergency hospital to anticipate the surge of new cas-
es in Jakarta. Wisma Atlet Kemayoran has a total of 
24,000 beds at maximum capacity.6 These facilities were 
intended to isolate asymptomatic, mild, and moderate 
cases to stop community transmission. Routine monitor-
ing was undertaken on each case, with those identified 
with worsening conditions to be transferred to referral 
hospitals.7 The emergency hospitals in Wuhan, China 
(such as Huoshenshan Hospital and Leishenshan 
Hospital) proved to approach disease containment suc-
cessfully.8 The characteristics of patients in this kind of 
emergency hospital in LMICs settings are still largely un-
known, especially during the early phase of the pandemic.
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In this study, the clinical characteristics, therapies, 
and outcomes of COVID-19 patients treated in the emer-
gency hospital were evaluated.
Method
Study Design and Population
      This retrospective study used data from all confirmed 
COVID-19 patients admitted to the National Emergency 
Hospital Wisma Atlet Kemayoran, Jakarta, from March 
23 to April 30, 2020. Patients were diagnosed according 
to the criteria of World Health Organization (WHO) in-
terim guidance. Patients with complete data of clinical, 
radiological, basic laboratory results were included in the 
analysis. The laboratory-confirmed case was defined as a 
case with a positive result on real-time reverse transcrip-
tion polymerase chain reaction (RT-PCR) for SARS-
CoV-2 in either the nasal or pharyngeal swab specimens 
irrespective of the clinical signs and symptoms. 
Data Collection
Data of all patients during the study period were ex-
tracted from the paper-based medical records into an 
electronic database. Age was recorded as continuous data 
but classified into three groups; 0-19 years, 20-49 years, 
and older than 50 years. Data related to signs and symp-
toms and the presence of comorbidity were recorded at 
admissions. The recorded symptoms were cough, sputum 
production, fever, dyspnea, sore throat, cold/runny nose, 
and anosmia. Comorbidities such as hypertension, dia-
betes, heart disease, asthma, and arthritis were recorded 
based on anamnesis. The peripheral blood test was taken 
at admission and measured hemoglobin, lymphocyte, 
white blood cell differential count, and platelets. 
Serological tests for detecting IgG and IgM antibodies 
against severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) were performed using commercially 
available immunochromatographic test (ICT) method 
with reactivity reported as IgG, IgM, or both. Chest X-
Ray (CXR) was used as a simple imaging study for all 
new cases during admission in this facility and reported 
as normal, increased broncho vascular markings, and 
consistent pneumonia. Real-time reverse transcription 
polymerase chain reaction (RT-PCR) for SARS-CoV-2 
detection conducted from nasal or pharyngeal swab spec-
imens in the central laboratory based on standard WHO 
protocol. The RT-PCR tests were measured on day one 
or day two, day 14, and day 15 as the end date of the iso-
lation period. 
Cases were classified into three different clinical clas-
sifications, i.e., asymptomatic, mild, and moderate, based 
on symptoms, laboratory, and radiological findings. An 
asymptomatic case is defined as no symptoms with nor-
mal laboratory and CXR findings despite a positive 
SARS-CoV-2 RT-PCR test. A mild case is a positive 
SARS-CoV-2 RT-PCR with acute non-specific upper res-
piratory tract symptoms but no sign of pneumonia. A 
moderate case is defined as positive SARS-CoV-2 RT-
PCR with clinical findings consistent with mild pneumo-
nia but where the patient does not require hospitaliza-
tion/is still able to perform daily activities. This clinical 
COVID-19 classification was under the direction of the 
Ministry of Health of the Republic of Indonesia COVID-
19 guidelines in March 2020.9 Since the nationally en-
dorsed guidelines were not established at that time, clin-
ical management of COVID-19 during the early phase of 
the pandemic in Indonesia was based on the consensus 
of five local professional organizations (5-OP/5 
Organisasi Profesi), i.e., Indonesian Society of 
Respirology, Indonesian Society of Internal Medicine, 
Indonesian Heart Association, Indonesian Society of 
Anesthesiologists and Intensive Therapy, and Indonesian 
Pediatric Society.10 Data regarding medication and clin-
ical outcomes during hospitalization were recorded.
Outcome Measures
      The first day of admission was recorded as the start 
of hospitalization, while discharge from the hospital 
was recorded as the end of hospitalization. Clinical 
outcomes were classified into whether recovery was 
reached or not. Recovered cases were defined as two 
consecutive negative SARS-CoV-2 RT-PCR results 
based on WHO guidelines. Furthermore, the conversion 
time–duration in days until RT-PCR result turned 
negative–and length of stay–duration of hospitalization 
in days–were also evaluated. The cases were followed up 
until April 30, 2020.
Data Analysis
     Patients’ demographic information and clinical cha-
racteristics were tabulated based on clinical 
classification of the disease for descriptive purposes. 
Differences between asymptomatic, mild, and 
moderate cases of COVID-19 were evaluated and 
tested either using one-way ANOVA or Kruskal-Wallis 
for continuous variables and either using Pearson’s Chi-
square or Fisher’s exact test for categorical 
variables, where appropriate. Statistical significance 
was considered to be a two-sided p-value <0.05. All 
analyses were performed using SPSS Version 25.0 for 
Mac (SPSS Inc., Chicago, IL, USA).
Result
Presenting Characteristics
  There were 1,070 cases admitted early in 
the pandemic, with 828 cases classified as 
COVID-19 confirmed cases and 415 discarded 
COVID-19 based on WHO case definition. Of 
the total confirmed cases, 382 cases had no 
CXR, 17 cases with no lab test, and 16 cases 
had no clinical baseline data. Four hundred 
thirteen cases were included in the analysis with 
a complete data set, with 55.4% (229) male and 
44.6% (184) female. The mean age was 39.9 years 
old, with the majority belonging to the 
productive-age group (20-49 age range). Older cases
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( >50 years) were more likely to be classified as moderate
cases as compared to the younger groups. In general, the
most common symptoms reported at onset were cough,
followed by fever, dyspnea, sore throat, runny nose, and
anosmia. Both in mild and moderate cases, the most com-
mon symptoms found were cough, fever, and dyspnea.
The 10% of cases had pre-existing comorbidities, of
which hypertension and diabetes were the commonest.
Those without comorbidity were more likely to be in the
asymptomatic group, as seen in Table 1.
Laboratory and Radiologic Findings
Abnormal laboratory findings such as reactive rapid 
serology test increased NLR, and lymphopenia was com-
monly reported. Other notable laboratory findings were 
thrombocytopenia and leucopenia. However, these labo-
ratory findings did not differ based on clinical classifica-
tion, as seen in Table 2. The normal radiologic finding 
was found in nearly half of all initial Chest X-Ray exam-
inations, and all moderate cases had CXR consistent with 
pneumonia. Increased broncho vascular markings were 
found more frequently in mild cases than asymptomatic 
cases.  
Table 1. Clinical Characteristics of COVID-19 Patients Admitted to
National Emergency Hospital Wisma Atlet Kemayoran
Characteristics Total Clinical degree
(n=413) p-value
Asymptomatic    Mild     Moderate
(n=190)       (n=93)     (n=130)
Sex 0.031
      Male 229 (55.4)   103 (54.2)   43 (46.2)   83 (63.8)
      Female 184 (44.6)     87 (45.8)   50 (53.8)   47 (36.2)
Age (in years) 39.9 (14.2)2 38.3           37.1           44.3    <0.0013
(14.7)         (11.5)        (14.1)
Age <0.0011
0-19 years 30 (7.3)     20 (10.5)       4 (4.3)       6 (4.6)
20-49 years             267 (64.6)   122 (64.2)   75 (80.6)   70 (53.8)
>50 years 116 (28.1)     48 (25.3)   14 (15.1)   54 (41.5)
Symptoms
      Cough 93 (22.5)         0 (0.0)   61 (65.6)   32 (24.6)    <0.0014
      Sputum production     15 (3.6)         0 (0.0)   13 (14.0)       2 (1.5)    <0.0014
      Fever 59 (14.3)         0 (0.0)   39 (41.9)   20 (15.4)    <0.0014
      Dyspnea 27 (6.5)         0 (0.0)   14 (15.1)   13 (10.0)    <0.0014
      Sore throat 22 (5.3)         0 (0.0)   15 (16.1)       7 (5.4)    <0.0014
      Cold/runny nose         20 (4.8)         0 (0.0)   10 (10.8)     10 (7.7)    <0.0014
      Anosmia 6 (1.5)         0 (0.0)       5 (5.4)       1 (0.8)     0.0024
Pre-existing comorbidity <0.0011
      Yes 43 (10.4)         7 (3.7)   18 (19.4)   18 (13.8)
      No 370 (89.6)   183 (96.3)   75 (80.6) 112 (86.2)
Comorbidities <0.0011
      None 370 (89.6)   183 (96.3)   75 (80.6) 112 (86.2)
      Hypertension 17 (4.1)         1 (0.5)       7 (7.5)       9 (6.9)
      Diabetes
      and Hypertension          4 (1.0)         2 (1.1)       0 (0.0)       2 (1.5)
      Diabetes 8 (1.9)         3 (1.6)       1 (1.1)       4 (3.1)
      Heart disease 3 (0.7)         0 (0.0)       2 (2.2)       1 (0.8)
      Asthma 2 (0.5)         0 (0.0)       2 (2.2)       0 (0.0)
      Arthritis 1 (0.2)         0 (0.0)       1 (1.1)       0 (0.0)
Notes: Values are means with standard deviations for continuous variables and n
(%) for frequencies. 1Pearson Chi-square, 2The median with the interquartile
range is presented, 3ANOVA, 4Fisher’s Exact Test
Table 2. Laboratory and Radiologic Findings of COVID-19 Patients Admitted to
National Emergency Hospital Wisma Atlet Kemayoran
Characteristics Total Clinical degree
(n=413) p-value
Asymptomatic    Mild      Moderate
(n=190)     (n=93)     (n=130)
Thrombocytopenia 7 (1.7)         2 (1.1)       1 (1.1)       4 (3.1)      0.391
      (<150000/uL)
Leucopenia 2 (0.5)         1 (0.5)       0 (0.0)       1 (1.1)      0.501
      (<4000/uL)
Lymphopenia (<20%)       45 (10.9)       17 (8.9)       9 (9.70   19 (14.6)      0.252
Increased NLR (>3.13)      76 (18.4)     31 (16.3)   15 (16.1)   30 (23.1)      0.252
Reactive rapid 202 (48.9)     89 (46.8)   44 (47.3)   69 (53.1)     0.782
serology test
Chest X-ray <0.0011
      Consistent with 
      Pneumonia                130 (31.5)         0 (0.0)       0 (0.0)  130 (100)
      Increased broncho
      vascular markings     110 (26.6)     71 (37.4)   39 (41.9) 0
      Normal                      173 (41.9)   119 (62.6)   54 (58.1) 0
Notes: Values are n (%) for frequencies, 1Fisher’s Exact Test, 2Pearson Chi-square
Table 3. Clinical Outcomes of COVID-19 Patients Admitted to National 
Emergency Hospital Wisma Atlet Kemayoran
Characteristics Total Clinical degree
(n=413) p-value
Asymptomatic    Mild      Moderate
(n=190)     (n=93)     (n=130)
Outcome 0.141
      Recovered 410 (99.3)    190 (100)   91 (97.8) 129 (99.2)
      Referred 1 (0.2)         0 (0.0)       1 (1.1)       0 (0.0)
      Discharged by 
      patient’s request 2 (0.5)         0 (0.0)       1 (1.1)       1 (0.8)
Conversion Time 
      Less than 14 days      196 (47.5)     80 (42.1)   48 (51.6)   68 (52.3)      0.132
      14 days or more        217 (52.5)   110 (57.9)   45 (48.4)   62 (47.7)
Length of stay (in days)      24 (15)4        25 (16)      22 (16)      24 (11)      0.203
Notes: Values are n (%) for frequencies, 1Fisher’s Exact Test, 2Pearson Chi-
Square, 3Kruskal Wallis Test, 4The median with the interquartile range is
presented.
Intervention and Outcome
Among 413 cases, data related to therapy were avail-
able in only 108 cases. All cases received vitamin C, 5.6%
of them also received Azithromycin, 10.2 % Oseltamivir 
and Azithromycin, 4.6% Oseltamivir and  
Hydrochloroquine, 7.4% Oseltamivir and Chloroquine, 
28.7% Oseltamivir with Hydrochloroquine and  
Azithromycin, 10.2% Oseltamivir with Chloroquine and 
Azithromycin, and 3.7% a combination of Chloroquine 
with Azithromycin and Levofloxacin. No adverse effects 
were reported in the majority of the cases (83.1%). 
Almost all patients recovered, and the median length of 
stay at the facility was 24 days. Conversion time varied 
between patients, with around half of them converted in 
less than 14 days and the other half in more than 14 days. 
Clinical classification did not seem to correlate with con-
version time and length of stay (Table 3).
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Discussion
   There were 828 confirmed cases of COVID-19 from 
a total of 1070 suspected cases admitted to the 
national emergency hospital during the early phase of 
the pandemic. A confirmed case is based on the WHO 
COVID case definition, of which positive SARS-
CoV-2 RT-PCR must be detected from 
nasopharyngeal/oropharyngeal swab.11 The 
number of cases not included in the analysis was 415 
cases due to incomplete data collection. During the 
early phase of the pandemic in this emergency hospi-
tal, the data management of all patients was based 
mainly on manual/paper-based records since the 
paperless system was still in preparation and 
most health care providers were volunteers. 
Additionally, 413 with a complete data set were ana-
lyzed. Clinical classification presenting in this study 
mainly was asymptomatic cases (46%), followed by mod-
erate and mild cases, respectively.  The high proportion 
of asymptomatic COVID-19 confirmed cases might be 
due to the nature of this national facility that intended to 
take care of asymptomatic, mild, and moderate cases. A 
study by Young et al., Michelen et al., Zhao et al. con-
ducted in general hospitals in each country showed about 
60-80% of cases reported asymptomatic to the mild clin-
ical condition.11–13 Another study in an emergency hos-
pital setting showed a different clinical condition propor-
tion in which asymptomatic cases were less than
10%.11,13
Confirmed case prevalence in males was about 1.24 
times higher than in females in this study. This result 
was consistent with two other previous studies that 
showed higher prevalence in the male population.12,14 
Almost 92% of the cases were younger than 60 years 
old with a mean age of 39,94±14,17 years old. This 
characteristic was slightly different from what Ma et al.  
reported in their studies where the median age of 49.8 
years old.14 In that study, severe cases were also 
included. Age as a predicting factor of  COVID-19 
severity was also reported (≥ 50 years old).14 This was 
consistent with the fact that younger people have more 
robust immune responses and tend to have a milder 
infection compared to their elder counterparts.15 
Therefore, is it likely that most asymptomatic covid 
confirmed cases were relatively younger.12,14,16 This 
study presented that almost 90%of the cases had no 
known comorbidity. Of those with comorbidities, 
hypertension and diabetes mellitus were the commonest. 
This characteristic is in line with a sys-tematic review 
by Ma et al.  that showed cerebrovascular 
disease, hypertension, and diabetes mellitus were 
the most prevalent comorbidities in COVID-19 with 
proportions of 6.75%, 4.48%, 4.43% consecutively.14
Clinical, Imaging, and Laboratory Characteristics of 
Confirmed Cases
In this study, the most common symptoms were cough 
and fever in almost 22.5% and 14.3% of cases, respec-
tively, followed by dyspnea, sore throat, and cold, in or-
der. Noor et al.  reported that nearly 80% of the cases 
showed respiratory symptoms, with the most prevalent 
cough and fever symptoms.17 Another systematic review 
reported gastrointestinal and neurologic symptoms fol-
lowing respiratory symptoms.14 The differences between 
studies might be affected by country demography, popu-
lation subjectivity, and subject honesty in each study set-
ting. This study did not record other gastrointestinal and 
neurological symptoms because it was based on early 
manual medical records limited to basic main symptoms.    
Chest X-Ray findings showed that about 40% of cases 
had a normal description, and 30% were consistent with 
pneumonia in all moderate cases. A study by Ma et al.  re-
ported 33% of abnormal imaging findings in infiltrate 
and crepitation based on CT scan.14 High-resolution CT 
scan of the chest was not possible in these facilities. 
Therefore CXR was conducted as a simple and affordable 
imaging modality. This study showed that CXR could be 
used as a baseline imaging in resource-limited settings. It 
was found that the reactive result of rapid serology test 
only in 50% of confirmed cases. This finding then led to 
differences in previous studies results reporting rapid 
serology test sensitivity, about 62.2%-83.8% for asymp-
tomatic and symptomatic cases.18,19 Differences between 
results might be affected by the examination method as 
well as the sensitivity and specificity of the examination 
tools in each study.  
Routine laboratory tests in this study were mainly 
within normal limits. About 20% of cases with abnormal 
findings included lymphopenia, leucopenia, and throm-
bocytopenia. This finding was in line with other stud-
ies.11,12,14,20 Interestingly, an NLR value of more than 
3.13 was also found in asymptomatic and mild clinical 
degree cases. Contrary to recent study findings, which re-
ported that NLR value >3.13 could be used as a reliable 
indicator of severe COVID-19.21 The different results 
found might be related to the variability of country de-
mography, clinical degree, and/or individual systemic im-
mune response used in each study. 
This study found no significant relationship between 
clinical condition and laboratory findings mentioned pre-
viously. A previous systematic review reported thrombo-
cytopenia, lymphopenia, and elevated d-dimer as negative 
prognostic factors.13 However, this study could not con-
clude since most cases were asymptomatic and mild. 
Lymphopenia and increased NLR appeared higher in the 
moderate cases than the asymptomatic and mild cases, 
although not statistically significant. Another study also 
reported lymphopenia (8.1%) and thrombocytopenia 
(2.7%) in asymptomatic cases.18 What might be inter-
Confirmed COVID-19 Case Proportion
General Characteristic of the Confirmed Case
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esting is that the proportion of lymphopenia and throm-
bocytopenia in asymptomatic case reporting was 37.8%
and 28.6%, respectively, higher than previously reported. 
Innate and adaptive immunity in this study population 
might differ in response to SARS-CoV-2, especially in 
asymptomatic and mild cases. Further study is needed to 
delineate this assumption.    
Outcomes
Ninety-nine percent of cases in this study were recov-
ered based on negative SARS-CoV-2 RT-PCR testing. Of 
note, 100% of asymptomatic cases recovered, only 1.1%
(1) mild case was referred to the referral hospital due to
worsening condition, and 0.5% (2 patients) were dis-
charged by request. None of the moderate cases became
progressed even though they had evidence of pneumonia
based on CXR and were given standard therapy. Since
there is no solid evidence for COVID definitive treat-
ment, standard therapy might be still be needed and
might play a role in COVID-19 recovery, especially in
asymptomatic, mild, and moderate cases.
This is different from the results of the study by Tian 
et al. , where 45 (17.2%) patients were discharged or re-
covered, 214 (81.7%) stayed in the hospital, and three 
patients died.16 Zhao et al. stated that out of 77 patients, 
64 patients were discharged, recovered, eight remained 
in treatment, and five died. Five patients died, and three 
of them were confirmed positive to COVID-19.11 The 
difference in the outcome of treatment in this study com-
pared to other studies might be due to the emergency 
hospital function of treating asymptomatic, mild, and 
moderate patients.
The mean length of stay in this study was 24 days and 
was similar across asymptomatic, mild, or moderate cas-
es. Conversion time among groups was also similar, with 
52.3% cases virologically converted after 14 days. It was 
because, during the early phase of the pandemic, only 
one central laboratory was able to run SARS-CoV-2 RT-
PCR tests and needed 5-7 working days to acquire the re-
sults. Young et al. found that from 18 subjects with con-
firmed COVID-19 in Singapore, there was a prolonged 
duration of conversion to 24 days after symptoms on-
set.12 Zhou et al. obtained a median duration of viral re-
tention of 20 (17-24) days from the onset in surviving 
patients and a maximum of 37 days.21
This study is among the first to have reported patients’ 
clinical characteristics and outcomes with COVID-19 
treated at the emergency hospital in Indonesia. However, 
this study’s limitations were that patients with incomplete 
data could not be included in the analysis. CXR data was 
missing in more than 40% of all COVID-19 patients in 
our hospital during the study period. This may cause the 
selection of study subjects, although we believe that this 
missingness was random and did not influence the 
validity of our findings.
Conclusion
Clinical characteristics of mild and asymptomatic cas-
es were similar, but moderate cases with signs of pneu-
monia are commonly found in this study. Asymptomatic, 
mild, and moderate COVID-19 confirmed cases mainly 
were recovered. Only a small proportion developed a se-
vere and progressive disease that needs further hospital-
ization. In emergency COVID care for mild/asympto-
matic/moderate cases, it was still necessary to monitor 
the patients for progressive disease and stop community 
transmission in resource-limited settings. Even a moder-
ate clinical condition with signs of pneumonia could be 
treated/monitored safely in an emergency hospital despite 
many challenges. Further studies should be directed to-
wards improving the quality of care and optimizing the 
role of the emergency hospital during the pandemic.
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